Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials

Edward K. Avila, Marc Chamberlain, David Schiff, Jaap C. Reijneveld, Terri S. Armstrong, Roberta Ruda, Patrick Y. Wen, Michael Weller, Johan A.F. Koekkoek, Sandeep Mittal, Yoshiki Arakawa, Ali Choucair, Jorge Gonzalez-Martinez, David R. MacDonald, Ryo Nishikawa, Aashit Shah, Charles J. Vecht, Paula Warren, Martin J. Van Den Bent, Lisa M. DeAngelis

Research output: Contribution to journalReview articleAcademicpeer-review

85 Citations (Scopus)


Patients with low-grade glioma frequently have brain tumor-related epilepsy, which is more common than in patients with high-grade glioma. Treatment for tumor-associated epilepsy usually comprises a combination of surgery, anti-epileptic drugs (AEDs), chemotherapy, and radiotherapy. Response to tumor-directed treatment is measured primarily by overall survival and progression-free survival. However, seizure frequency has been observed to respond to tumor-directed treatment with chemotherapy or radiotherapy. A review of the current literature regarding seizure assessment for low-grade glioma patients reveals a heterogeneous manner in which seizure response has been reported. There is a need for a systematic approach to seizure assessment and its influence on health-related quality-of-life outcomes in patients enrolled in low-grade glioma therapeutic trials. In view of the need to have an adjunctive metric of tumor response in these patients, a method of seizure assessment as a metric in brain tumor treatment trials is proposed.

Original languageEnglish
Pages (from-to)12-21
Number of pages10
Issue number1
Publication statusPublished - 2017


  • Glioma
  • Low-grade
  • Metric
  • Scale
  • Seizures

Cite this